news
Increasing dose of statins could save more lives
A study has shown that thousands of heart attacks and deaths caused by cardiovascular disease could be prevented through the use of statins...
List view / Grid view
Cardiovascular disease
news
3D bioprinting technique for artificial organ tissue and arteries
A 3D bioprinting technique could, in the future, allow the creation of human tissue structures for the analysis of various diseases...
news
Manufacturing small batches of biopharmaceuticals on demand
Portable biopharmaceutical drug manufacturers could be the future method of producing the drugs on demand for outbreaks of disease...
news
Statins study questions their widespread use in the healthy elderly
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
news
Cardiac monitoring for high-risk breast cancer patients ‘should be prioritised’
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
news
Heart health calculator predicts CVD risk
A new online heart health calculator can predict the age of hearts and the risk to individuals of a serious cardiovascular event or death...
news
Canakinumab reduces gout rate by more than half
The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half, compared to placebo, regardless of baseline serum urate level.
news
Nutrition, the microbiome, and Autism Spectrum Disorder: A review
Over the last decade, research has revealed more about the human gut microbiome—the environment within the gastrointestinal tract—where microbes, especially bacteria, reside.
news
Novartis invests in Ionis’ therapies to reduce cardiovascular risk
10 January 2017 | By Niamh Marriott, Digital Editor
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
news
FDA to review 3 new diabetes drugs that reduce cardiovascular death risk
5 January 2017 | By Niamh Marriott, Digital Editor
In the trial, empagliflozin significantly reduced the relative risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack by 14%...
news
Novo Nordisk’s semaglutide reduced major cardiovascular events in 1 in 4 type 2 diabetic adults
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent...
news
New data adds to understanding of Repatha® (evolocumab) in multiple patient populations
23 August 2016 | By Amgen
Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome...
news
Controversy, media coverage and statin use in the UK
28 June 2016 | By Victoria White, Digital Content Producer
A study has found that controversy over the risks and benefits of statins was followed by an increase in people stopping their statin treatment...
news
Results in from Phase III CHART-1 study of C-Cure
28 June 2016 | By Victoria White, Digital Content Producer
Celyad has announced headline results for CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate - C-Cure...
news
NICE recommends alirocumab and evolocumab in draft guidance
6 May 2016 | By Victoria White, Digital Content Producer
Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia...
